TetraSOD® Supplementation and Skeletal Muscle Redox Gene Expression
NCT ID: NCT06822556
Last Updated: 2025-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2021-11-05
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study assessed the effect of short-term TetraSOD supplementation on human skeletal muscle antioxidant gene expression in healthy adults.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TetraSOD® Supplementation and Exercise Performance
NCT06831656
Strength Training and Resveratrol
NCT06585865
Spirulina Platensis Supplementation and Calorie Restriction in Obese Men : A Randomized Controlled Trial Protocol Study
NCT06076161
The Effect of Antioxidant Vitamin Supplementation on Muscle Performance and Redox Status After Eccentric Training
NCT01290458
Iron Supplementation and Eccentric Exercise
NCT02374619
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study assessed the effect of short-term TetraSOD supplementation on human skeletal muscle antioxidant gene expression in healthy adults.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo supplementation
Placebo
14 days of supplementation with 25 mg/day hemicellulose crystalline
Tetraselmis chuii
Tetraselmis chuii supplementation
Tetraselmis chuii
14 days of supplementation with 25 mg/day tetraselmis chuii
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
14 days of supplementation with 25 mg/day hemicellulose crystalline
Tetraselmis chuii
14 days of supplementation with 25 mg/day tetraselmis chuii
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult (aged ≥18 and ≤40 years old)
* Recreationally-active (≥2 and ≤4 exercise sessions per week) and a VO2max of ≥ 35 mL/kg/min and ≤ 65 mL/kg/min as determined from the preliminary exercise test
* No known history of gastric, digestive, cardiovascular, renal disease or any other orthopaedic diseases related to motor organs
* Non-smoker
* Healthy body mass index (BMI; ≥18.5 and ≤24.9 kg/m2)
* Not using any dietary supplements, including antioxidant and nitrate-rich supplements, currently or in the past one month
* Not a heavy drinker (≤ 14 units of alcohol) on most weeks
* Not using medication that may affect study measures
* Not participating in other studies currently or in the past two months prior to the consenting session (visit 1) or having an intention to participate in other studies over the period of this study
Exclusion Criteria
* Aged \<18 and \>40 years old
* Sedentary or highly trained with a respective V#O2max of \< 35 mL/kg/min and \> 65 mL/kg/min as determined from the preliminary exercise test
* History of gastric, digestive, cardiovascular, renal disease or any other orthopaedic diseases related to motor organs
* Smoker
* Unhealthy body mass index (BMI;\<18.5 and \>24.9 kg/m2)
* Using any dietary supplements, including antioxidant and nitrate-rich supplements, currently or in the past one month
* Heavy drinker (\> 14 units of alcohol) on most weeks
* Using medication that may affect study measures
* Participating in other studies currently or in the past two months prior to the consenting session (visit 1) or having an intention to participate in other studies over the period of this study
Participants will be excluded from the biopsy sub-set if they report any of the following:
* Allergy to Lidocaine or any of the ingredients. Symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue, or other parts of the body, rash, itching or hives on the skin.
* Infection or swelling where the injection will be given
* Blood infections or disorders
* In severe shock
* Low blood pressure
* Disease of the brain or spinal cord
* Sudden frequent episodes of loss of consciousness
* Myasthenia gravis, a severe muscle weakness
* Heart problems
Furthermore, Lidocaine injection will NOT be used in cases of:
* Severely disturbed cardiac conduction
* Bradycardia
* ADAMS-STOKES syndrome
* Wolfe Parkinson White syndrome
* Sudden heart failure
* Hypersensitivity to amide-type local anaesthetics
* Suspicion of hereditary tendency to malignant hyperthermia
* Disorders of blood coagulation
* Infection of the region to be injected
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fitoplancton Marino, S.L.
INDUSTRY
Loughborough University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen Bailey
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Bailey
Role: PRINCIPAL_INVESTIGATOR
Loughborough University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loughborough University
Loughborough, United Kingdom, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-6116-5434
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.